Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Inhibition of SLPI ameliorates disease activity in experimental autoimmune encephalomyelitis.
Evaluating the potential benefit of interferon treatment in multiple sclerosis.
Teva to initiate third Phase III trial of oral laquinimod for the treatment of relapsing remitting multiple sclerosis
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Genetic burden of common variants in progressive and bout-onset multiple sclerosis.
Fatigue and fatigability in neurologic illnesses: Proposal for a unified taxonomy.
Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses.
Mobile phones and multiple sclerosis - a nationwide cohort study in denmark.
[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
Role of statins in the treatment of multiple sclerosis.
Phenytoin protects central axons in experimental autoimmune encephalomyelitis.
Psychiatric disorders in neurology.
Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases.
Embryonic stem cell lines derived from human blastocysts.
Erythropoietin for acute multiple sclerosis in patients with optic neuritis as a first demyelination event.
Acute disseminated encephalomyelitis--a prospective study of clinical profile and in-hospital outcome predictors.
Postmarketing Safety Profile of Subcutaneous Interferon Beta-1a Given 3 Times Weekly: A Retrospective Administrative Claims Analysis.
Substance Name: Naltrexone
Cytokines and Disability in Interferon-β-1b Treated and Untreated Women with Multiple Sclerosis.
The initiation and prevention of multiple sclerosis.
Interferon beta 1a-induced severe autoimmune hepatitis in patients with multiple sclerosis: report of two cases and review of the literature.
Genzyme receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) application
Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening.
Reward responsiveness and fatigue in multiple sclerosis.
Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System.

Pages